Cantor Fitzgerald Forecasts Verastem FY2025 Earnings

Verastem, Inc. (NASDAQ:VSTM - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Verastem in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the biopharmaceutical company will post earnings per share of ($3.24) for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Verastem's current full-year earnings is ($3.02) per share.

A number of other research analysts have also commented on the company. Royal Bank of Canada upped their price target on Verastem from $13.00 to $16.00 and gave the stock an "outperform" rating in a report on Tuesday, January 7th. Guggenheim assumed coverage on shares of Verastem in a research note on Monday, September 30th. They set a "buy" rating and a $13.00 target price for the company. StockNews.com lowered shares of Verastem from a "hold" rating to a "sell" rating in a research report on Tuesday, November 19th. Mizuho boosted their price objective on shares of Verastem from $7.00 to $9.00 and gave the stock an "outperform" rating in a report on Thursday, December 19th. Finally, HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of Verastem in a research note on Thursday, December 19th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $13.38.

Verastem Stock Performance

Shares of NASDAQ VSTM traded up $0.07 during trading hours on Thursday, hitting $5.59. 863,636 shares of the company's stock were exchanged, compared to its average volume of 1,769,517. The stock has a market capitalization of $248.81 million, a price-to-earnings ratio of -1.75 and a beta of 0.24. The company's 50-day moving average price is $4.88 and its 200-day moving average price is $3.61. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.23 and a quick ratio of 3.23. Verastem has a 1-year low of $2.10 and a 1-year high of $14.22.

Verastem (NASDAQ:VSTM - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.11.

Insider Activity at Verastem

In other news, CEO Dan Paterson sold 8,568 shares of the company's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $5.24, for a total value of $44,896.32. Following the sale, the chief executive officer now owns 347,581 shares of the company's stock, valued at approximately $1,821,324.44. This represents a 2.41 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 10,321 shares of company stock valued at $52,217 over the last quarter. 2.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Verastem

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Walleye Capital LLC raised its holdings in shares of Verastem by 493.7% in the third quarter. Walleye Capital LLC now owns 216,126 shares of the biopharmaceutical company's stock valued at $646,000 after buying an additional 179,725 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Verastem by 67.6% in the third quarter. Geode Capital Management LLC now owns 890,599 shares of the biopharmaceutical company's stock worth $2,663,000 after acquiring an additional 359,060 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Verastem during the second quarter worth approximately $1,192,000. XTX Topco Ltd bought a new stake in shares of Verastem during the third quarter valued at approximately $112,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Verastem in the third quarter valued at approximately $43,000. 88.37% of the stock is currently owned by institutional investors and hedge funds.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.